Outlook Therapeutics to Present at the Virtual Investor Fireside Chat Series
June 09 2020 - 8:05AM
Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the Company), a late
clinical-stage biopharmaceutical company working to develop the
first FDA-approved ophthalmic formulation of bevacizumab for use in
retinal indications, today announced that Lawrence A. Kenyon,
President, CEO and CFO of Outlook Therapeutics, will present at the
Virtual Investor Fireside Chat Series on Wednesday, June 17, 2020
at 2:00 PM ET.
A live video webcast of the fireside chat will be available on
the Events page of the Investors section of the Company’s website
(outlooktherapeutics.com). Immediately following the fireside chat,
management will participate in an interactive Q&A session with
interested parties, allowing participants to type in questions and
receive live responses. A webcast replay will be available two
hours following the live presentation and will be accessible for
one year.
To schedule a one-on-one call with management, please submit a
request through the conference website vifiresidechat.com, or
contact the conference at info@virtualinvestorco.com. For more
information about the event, please visit vifiresidechat.com.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a late clinical-stage biopharmaceutical
company working to develop the first FDA-approved ophthalmic
formulation of bevacizumab for use in retinal indications,
including wet AMD, DME and BRVO. If ONS-5010 / LYTENAVA™
(bevacizumab vikg), its investigational ophthalmic formulation of
bevacizumab, is approved, Outlook Therapeutics expects to
commercialize it as the first and only approved ophthalmic
formulation of bevacizumab for use in treating approved retinal
diseases in the United States, Europe, Japan and other markets.
Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as
a new BLA under the PHSA 351(a) regulatory pathway. For more
information, please visit www.outlooktherapeutics.com.
CONTACTS: Outlook
Therapeutics: Lawrence A. Kenyon
LawrenceKenyon@outlooktherapeutics.com
Investor Inquiries: Jenene Thomas Chief
Executive Officer JTC Team, LLC T: 833.475.8247
OTLK@jtcir.com
Media Inquiries:Emmie TwomblyMedia Relations
SpecialistLaVoie Health ScienceM:
857.389.6042etwombly@lavoiehealthscience.com
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Sep 2023 to Sep 2024